This is a randomized controlled clinical trial designed to evaluate the therapeutic effects of Montelukast in patients diagnosed with Acute Myocardial Infarction (AMI). The study aims to investigate whether the administration of Montelukast influences inflammatory markers and the extent of cardiac injury following a heart attack.Participants will be randomly assigned to receive either the active medication or a placebo to provide high-quality evidence regarding the drug's potential cardioprotective and anti-inflammatory properties. The trial is conducted through the Faculty of Pharmacy and Faculty of Medicine at Mansoura University
Age 30-75 years Diagnosed with STEMI within 6 hours of symptom onset Undergoing PCI or thrombolysis Eligible for standard ACS therapy signed Informed consent
Chronic use of anti-inflammatory drugs
Severe hepatic or renal impairment
Hypersensitivity to Montelukast
Autoimmune or inflammatory diseases
Parallel
Montelukast 10 Mg Oral Tablet
DrugMontelukast 10 Mg Oral Tablet
placebo
Other interventionplacebo
Change in inflammatory biomarkers (IL-6, TNF-α, hs-CRP, Galectin-3, LTB4)
This outcome measures the change in inflammatory biomarkers (IL-6, TNF-α, hs-CRP, Galectin-3, and LTB4) from baseline to day 3 and week 4 in patients receiving MoThis outcome measures the change in inflammatory biomarkers (IL-6, TNF-α, hs-CRP, Galectin-3, and LTB4) from baseline to day 3 and week 4 in patients receiving Montelukast compared to placebo. ntelukast compared to placebo.
Click on the lead sponsor to view all of their trials.
October 6 University
Lead sponsor
Mansoura University
Collaborator
